Last reviewed · How we verify
Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone
Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone is a Multi-agent chemotherapy regimen Small molecule drug developed by St. Jude Children's Research Hospital. It is currently in Phase 3 development for Acute leukemia in pediatric patients.
This is a multi-drug chemotherapy regimen that combines nucleoside analogs, alkylating agents, and anthracyclines to kill rapidly dividing leukemic cells through DNA damage and inhibition of DNA synthesis.
This is a multi-drug chemotherapy regimen that combines nucleoside analogs, alkylating agents, and anthracyclines to kill rapidly dividing leukemic cells through DNA damage and inhibition of DNA synthesis. Used for Acute leukemia in pediatric patients.
At a glance
| Generic name | Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone |
|---|---|
| Sponsor | St. Jude Children's Research Hospital |
| Drug class | Multi-agent chemotherapy regimen |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Cladribine and cytarabine are nucleoside analogs that inhibit DNA synthesis in leukemic blasts. Cyclophosphamide is an alkylating agent that cross-links DNA. Daunorubicin is an anthracycline that intercalates into DNA and inhibits topoisomerase II. Dexamethasone is a corticosteroid that enhances the cytotoxic effects and reduces inflammation. Together, these agents target leukemic cells through multiple mechanisms of DNA damage and cell death.
Approved indications
- Acute leukemia in pediatric patients
Common side effects
- Myelosuppression
- Infection
- Mucositis
- Nausea and vomiting
- Cardiotoxicity
- Alopecia
- Hemorrhage
Key clinical trials
- German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003) (PHASE4)
- Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia (PHASE3)
- German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone CI brief — competitive landscape report
- Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone updates RSS · CI watch RSS
- St. Jude Children's Research Hospital portfolio CI
Frequently asked questions about Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone
What is Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone?
How does Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone work?
What is Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone used for?
Who makes Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone?
What drug class is Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone in?
What development phase is Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone in?
What are the side effects of Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone?
Related
- Drug class: All Multi-agent chemotherapy regimen drugs
- Manufacturer: St. Jude Children's Research Hospital — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Acute leukemia in pediatric patients
- Compare: Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone vs similar drugs
- Pricing: Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone cost, discount & access